SciELO - Scientific Electronic Library Online

vol.88 issue5cycEVA study: case control study measuring influenza vaccine effectiveness in Spain, 2008-2013Different methods used to estimate the prevalence of hypothyroidism, Cadiz, Spain author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista Española de Salud Pública

On-line version ISSN 2173-9110Print version ISSN 1135-5727


PUEYO VELASCO, José Ignacio  and  REJAS GUTIERREZ, Javier. Review of patient reported outcomes in the summary of the product characteristics of medicines approved in Spain. Rev. Esp. Salud Publica [online]. 2014, vol.88, n.5, pp.613-627. ISSN 2173-9110.

Background: The term "Patient Reported Outcomes" (PRO) is defined as any result assessed directly by the patient and based on his perception of the illness and its treatment. The scope of the study is to determine and compare the use of PRO measures with other types of effectiveness endpoints in the summary of the products characteristics (SPC) of medicines with active substances approved by first time from 2000 to 2012 in Spain. Methods: A review and descriptive analysis of the effectiveness endpoints used in the clinical trials described in the SPCs studied, classifying them into the following categories: PRO, clinician-reported outcomes (CROs), and laboratory test/device measurement endpoints (ML). Chi-square and Fisher exact texts were used for comparative purposes, and odds ratio to determine the strongest of association. Results: PROs were included in 65 (19.7%) of the SPCs studied. CRO were the most frequently reported 188 (57%) cases, followed by ML:128 (38,7%). PROs were included as only effectiveness endpoint in 6 medicines. A growing trend toward statistical significance (R2=0.525; p=0.079) has been observed in reporting PROs during the period of time studied. Conclusion: The use frequency of PRO in SPCs is clearly minor compared to other efficacy endpoints considered, being the difference significantly higher in case of its use as only efficacy endpoint. The therapeutic areas where PROs were most reported were nervous system medicines, immunologic system modulator medicines, respiratory system, muscle and skeleton system.

Keywords : Patient outcome assessment; Drug labeling; Drug approval; Quality of life.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License